Transgenic Group (TSE:2342) Other Current Payables: 円228 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2342 Transgenic Group Inc TSE:2342
61 GF Score
Price 円211.00
GF Value 円258.37
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Transgenic Group Other Current Payables?

Transgenic Group TSE:2342 -1.86% 61 Other Current Payables is 円228 Mil as of Mar. 2026. GuruFocus rates TSE:2342 with a GF Score™ of 61/100 and a GF Value™ of 円258.37 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Transgenic Group's Other Current Payables for the quarter that ended in Mar. 2026 was 円228 Mil.

Transgenic Group's quarterly Other Current Payables increased from Mar. 2025 (円223 Mil) to Sep. 2025 (円240 Mil) but then declined from Sep. 2025 (円240 Mil) to Mar. 2026 (円228 Mil).

Transgenic Group's annual Other Current Payables declined from Mar. 2024 (円239 Mil) to Mar. 2025 (円223 Mil) but then increased from Mar. 2025 (円223 Mil) to Mar. 2026 (円228 Mil).

Transgenic Group Other Current Payables Related Terms

Transgenic Group Other Current Payables Historical Data

* Premium members only.

The historical data trend for Transgenic Group's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgenic Group Other Current Payables Chart

Transgenic Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 424.60 284.02 238.72 223.35 227.80

Transgenic Group Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 238.72 428.25 223.35 240.14 227.80
TSE:2342
61GF Score
Transgenic Group Inc TSE:2342
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgenic Group Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円228 Mil mean?
Transgenic Group (TSE:2342) has a Other Current Payables of 円228 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Transgenic Group and its competitors.
Is Transgenic Group's Other Current Payables too high?
Transgenic Group's current Other Current Payables is 円228 Mil. Overall, Transgenic Group has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Other Current Payables compare to VRTX and REGN?
Transgenic Group's Other Current Payables of 円228 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Transgenic Group and its competitors. Transgenic Group's current Other Current Payables is 円228 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円258.37, compared to a current price of 円211.00 — trading 18.3% below its estimated fair value. The current Other Current Payables is 円228 Mil. Transgenic Group's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Other Current Payables is 円228 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgenic Group (TSE:2342) Overvalued in 2026?

Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued. The current stock price of 円211.00 is trading 18.3% below its estimated GF Value™ of 円258.37. GuruFocus considers Transgenic Group to be Modestly Undervalued.

Key valuation signals for TSE:2342:

  • Other Current Payables: 円228 Mil
  • GF Value™: 円258.37 vs. price of 円211.00 (18.3% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgenic Group Business Description

Address 2-3-36 Tenjin, Chuo-ku, Fukuoka Prefecture, Fukuoka, JPN
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
61GF Score

Get the complete analysis for TSE:2342

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円211.00
Price
円258.37
GF Value